{"title":"Treatment of recurrent uveitis and ankylosing spondylitis with golimumab: a case report, Letter to Editor","authors":"Maysoun Kudsi, Tasneem Drie, Sumaya Dumirieh","doi":"10.1097/ms9.0000000000002342","DOIUrl":null,"url":null,"abstract":"\n \n Uveitis, as an extra-articular presentation, is found in 23% of patients with Ankylosing Spondylitis and is a challenging disease to treat.\n \n \n \n we presented A 32-year-old male presented to the out-hospital, complaining of recurrent anterior uveitis 8 years earlier in his left eye, and suffered from inflammatory lumber pain for 2 years. so a diagnosis of Ankylosing Spondylitis(AS) after the failure of many therapeutic strategies, 50 mg /month subcutaneous Golimumab was started with clinical remission of AS and uveitis.\n \n \n \n The American College of Rheumatology 10 recommends the use of etanercept and adalimumab in the treatment of recurrent uveitis in AS patients. Similarly, the European League Against Rheumatism11 recommended using Infliximab, Adalimumab, or Certolizumab to prevent the recurrence of uveitis recurrence. Till now, a case about treating refractory uveitis with Golimumab in AS patients was published1.\n \n \n \n Golimumab was found to be effective in the treatment of uveitis associated with spondyloarthritis refractory at least one immunosuppressive drug.\n","PeriodicalId":503882,"journal":{"name":"Annals of Medicine & Surgery","volume":"2 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Medicine & Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ms9.0000000000002342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Uveitis, as an extra-articular presentation, is found in 23% of patients with Ankylosing Spondylitis and is a challenging disease to treat.
we presented A 32-year-old male presented to the out-hospital, complaining of recurrent anterior uveitis 8 years earlier in his left eye, and suffered from inflammatory lumber pain for 2 years. so a diagnosis of Ankylosing Spondylitis(AS) after the failure of many therapeutic strategies, 50 mg /month subcutaneous Golimumab was started with clinical remission of AS and uveitis.
The American College of Rheumatology 10 recommends the use of etanercept and adalimumab in the treatment of recurrent uveitis in AS patients. Similarly, the European League Against Rheumatism11 recommended using Infliximab, Adalimumab, or Certolizumab to prevent the recurrence of uveitis recurrence. Till now, a case about treating refractory uveitis with Golimumab in AS patients was published1.
Golimumab was found to be effective in the treatment of uveitis associated with spondyloarthritis refractory at least one immunosuppressive drug.
葡萄膜炎是强直性脊柱炎的一种关节外表现,在23%的强直性脊柱炎患者中发现,是一种治疗难度很大的疾病。我们介绍了一位32岁的男性患者,主诉8年前左眼复发性前葡萄膜炎,并伴有2年的炎性腰痛,因此被诊断为强直性脊柱炎(AS),在多种治疗策略失败后,开始使用50毫克/月的皮下注射戈利木单抗,强直性脊柱炎和葡萄膜炎临床缓解。 美国风湿病学会(American College of Rheumatology 10)建议使用依那西普(etanercept)和阿达木单抗(adalimumab)治疗强直性脊柱炎患者的复发性葡萄膜炎。同样,欧洲抗风湿病联盟(European League Against Rheumatism)11 也建议使用英夫利西单抗(Infliximab)、阿达木单抗(Adalimumab)或赛妥珠单抗(Certolizumab)来预防葡萄膜炎复发。迄今为止,已有一例 AS 患者使用戈利木单抗治疗难治性葡萄膜炎的病例发表1。 研究发现,戈利木单抗可有效治疗至少一种免疫抑制剂难治的脊柱关节炎相关葡萄膜炎。